<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004873</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 42/99</org_study_id>
    <secondary_id>SWS-SAKK-42/99</secondary_id>
    <secondary_id>EU-99021</secondary_id>
    <nct_id>NCT00004873</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer</brief_title>
  <official_title>Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not&#xD;
      yet known which combination chemotherapy regimen is most effective in treating advanced&#xD;
      stomach cancer.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to compare the effectiveness of different regimens of&#xD;
      combination chemotherapy in treating patients who have advanced stomach cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy and tolerability of docetaxel, cisplatin, and fluorouracil (TCF)&#xD;
           versus docetaxel and cisplatin (TC) versus epirubicin, cisplatin, and fluorouracil (ECF)&#xD;
           in patients with advanced gastric carcinoma.&#xD;
&#xD;
        -  Compare the time to treatment failure, time to progression, and survival in this patient&#xD;
           population treated with these regimens.&#xD;
&#xD;
        -  Compare the quality of life during the treatment period and after failure in this&#xD;
           patient population.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to&#xD;
      center, performance status (0 vs 1), and liver involvement (yes vs no). Patients are&#xD;
      randomized to one of three treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive epirubicin IV bolus and cisplatin IV over 4 hours on day 1 plus&#xD;
           fluorouracil IV continuously on days 1-21.&#xD;
&#xD;
        -  Arm II: Patients receive docetaxel IV over 1 hour and cisplatin IV over 4 hours on day&#xD;
           1.&#xD;
&#xD;
        -  Arm III: Patients receive docetaxel and cisplatin as in arm II and fluorouracil as in&#xD;
           arm I.&#xD;
&#xD;
      Treatment regimen is repeated every 3 weeks for up to 8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed before randomization; at day 1 of courses 2, 4, and 6; and one&#xD;
      month after treatment failure.&#xD;
&#xD;
      Patients with complete response or partial response are followed monthly for 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 111 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed gastric carcinoma not amenable to curative surgery or in&#xD;
             relapse after primary surgical resection&#xD;
&#xD;
               -  Locally advanced disease (i.e., measurable locoregional lymph nodes) OR&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Bidimensionally measurable disease&#xD;
&#xD;
               -  At least 10 mm X 20 mm by chest x-ray or physical examination&#xD;
&#xD;
               -  At least 10 mm X 10 mm by CT scan&#xD;
&#xD;
          -  No CNS metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 70&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  0-1&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Greater than 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC count at least 4,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  BUN normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No severe hypercalcemia&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No unstable cardiac disease requiring treatment&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No angina pectoris even if medically controlled&#xD;
&#xD;
          -  No significant arrhythmias&#xD;
&#xD;
          -  No prior myocardial infarction unless ejection fraction at least 50% by MUGA scan or&#xD;
             echocardiogram&#xD;
&#xD;
        Neurologic:&#xD;
&#xD;
          -  No prior significant neurologic or psychiatric disorders, including psychotic&#xD;
             disorders, dementia or seizures that would preclude study&#xD;
&#xD;
          -  No peripheral neuropathy of any origin (alcohol, etc.) greater than grade 1&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Fertile patients must use adequate contraception&#xD;
&#xD;
          -  No prior malignancy except basal cell skin cancer or adequately treated carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No other serious illness or medical condition that would preclude study participation&#xD;
&#xD;
          -  No contraindication to corticosteroid use&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior palliative chemotherapy&#xD;
&#xD;
          -  At least 12 months since prior adjuvant or neoadjuvant chemotherapy&#xD;
&#xD;
          -  No prior taxanes&#xD;
&#xD;
          -  Prior fluorouracil allowed in bolus form only&#xD;
&#xD;
          -  Prior cumulative dose of adjuvant or neoadjuvant cisplatin no greater than 300 mg/m2&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Prior or concurrent prednisone (or equivalent) allowed for prophylaxis, acute&#xD;
             hypersensitivity reactions, or chronic therapy (greater than 6 months) at doses no&#xD;
             greater than 20 mg&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent experimental drugs&#xD;
&#xD;
          -  No other concurrent anticancer therapies&#xD;
&#xD;
          -  At least 30 days since treatment in prior clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud Roth, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hopital Cantonal Universitaire de Geneve</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, Koberle D, Borner MM, Rufibach K, Maibach R, Wernli M, Leslie M, Glynne-Jones R, Widmer L, Seymour M, de Braud F; Swiss Group for Clinical Cancer Research. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007 Aug 1;25(22):3217-23. doi: 10.1200/JCO.2006.08.0135.</citation>
    <PMID>17664469</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>March 7, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>May 14, 2012</last_update_submitted>
  <last_update_submitted_qc>May 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

